Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ustekinumab in anti-TNF-naive adults with active radiographic axial spondyloarthritis
2014-003679-48Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in ankylosing spondylitis (AS) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants achieving ASAS40 response at Week 24. Started Sep 2015; status: terminated.
02
Drugs
ustekinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2014-003679-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003679-48.